MAPK1 overexpression	Squamous Cell Carcinoma of Head and Neck	MAPK1 overexpression	Squamous Cell Carcinoma of Head and Neck	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
MAPK1 R135K	Squamous Cell Carcinoma of Head and Neck	MAPK1 R135K	Squamous Cell Carcinoma of Head and Neck	erlotinib Sensitive: D – Preclinical erlotinib Sensitive : D	erlotinib Sensitive: D – Preclinical erlotinib Sensitive : D
MAPK1 E322K	Squamous Cell Carcinoma of Head and Neck	MAPK1 E322K	Squamous Cell Carcinoma of Head and Neck	erlotinib Sensitive: D – Preclinical erlotinib Sensitive : D	erlotinib Sensitive: D – Preclinical erlotinib Sensitive : D
MAPK1 D321N	Squamous Cell Carcinoma of Head and Neck	MAPK1 D321N	Squamous Cell Carcinoma of Head and Neck	erlotinib Sensitive: D – Preclinical erlotinib Sensitive : D	erlotinib Sensitive: D – Preclinical erlotinib Sensitive : D
MAPK1 overexpression	Melanoma	MAPK1 overexpression	Melanoma	cisplatin Resistant: D – Preclinical cisplatin Resistant : D	cisplatin Resistant: D – Preclinical cisplatin Resistant : D

MAPK1 (Mitogen-activated protein kinase 1)

Associations(5)